Compare RRX & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RRX | KRYS |
|---|---|---|
| Founded | 1955 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.6B | 7.8B |
| IPO Year | 1994 | 2017 |
| Metric | RRX | KRYS |
|---|---|---|
| Price | $209.28 | $266.32 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 11 |
| Target Price | $209.70 | ★ $297.60 |
| AVG Volume (30 Days) | ★ 941.2K | 223.8K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.67% | N/A |
| EPS Growth | 42.86 | ★ 128.00 |
| EPS | 4.20 | ★ 6.84 |
| Revenue | ★ $3,257,100,000.00 | $389,130,000.00 |
| Revenue This Year | $4.15 | $39.88 |
| Revenue Next Year | $12.25 | $34.38 |
| P/E Ratio | $49.58 | ★ $37.88 |
| Revenue Growth | 5.21 | ★ 33.94 |
| 52 Week Low | $94.42 | $123.03 |
| 52 Week High | $229.30 | $298.30 |
| Indicator | RRX | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 61.80 | 57.53 |
| Support Level | $136.55 | $255.65 |
| Resistance Level | $227.65 | $293.60 |
| Average True Range (ATR) | 8.13 | 9.04 |
| MACD | 3.16 | 1.74 |
| Stochastic Oscillator | 97.89 | 84.13 |
Regal Rexnord Corp is in the engineering and manufacturing of industrial powertrain solutions, power transmission components, electric motors, electronic controls, air-moving products, and specialty electrical components and systems, serving customers around the world. The three operating segments include Automation & Motion Control (AMC) segment; Industrial Powertrain Solutions (IPS) segment, which derives maximum revenue; and Power Efficiency Solutions (PES) segment. Geographically, the company operates in North America, Europe, Asia, and Rest of the world, of which it derives maximum revenue from North America.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.